Progress in research of economic evaluation of COVID-19 vaccination strategies.
10.3760/cma.j.cn112338-20211210-00967
- Author:
Jing Yu ZHAO
1
;
Pei En HAN
1
;
Ya Qun FU
1
;
Li YANG
1
;
Tao REN
1
;
Si Yan ZHAN
1
;
Li Ming LI
2
Author Information
1. School of Public Health, Peking University, Beijing 100191, China.
2. School of Public Health, Peking University, Beijing 100191, China Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing 100191, China.
- Publication Type:Journal Article
- MeSH:
COVID-19/prevention & control*;
COVID-19 Vaccines;
China/epidemiology*;
Cost-Benefit Analysis;
Humans;
Vaccination
- From:Chinese Journal of Epidemiology
2022;43(4):460-465
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To understand the research progresses of economic evaluation of COVID-19 vaccination strategies both at home and abroad, and provide reference for the economic evaluation of COVID-19 vaccination strategies using real word data in China. Methods: Literature retrieval was conducted for related papers published from January, 2020 to December, 2021 in Chinese and English databases, including the economic evaluation of COVID-19 vaccination, and the results of the related literatures were narratively integrated. Results: A total of 16 English literatures (including 3 reviews) were included, and it was found that the COVID-19 vaccination was cost-effective or cost-saving regardless of the vaccine types, while the cost-effectiveness in different population and under different vaccination dose strategies varied due to vaccine efficacy, vaccine price, duration of natural immunity, duration of vaccination campaign, vaccine supply, and vaccination pace. Conclusions: China lacks suitable evidences of economic evaluation of COVID-19 vaccination strategies based on real-world data in the context of long-term epidemic. Therefore, further researches of suitable strategies of booster COVID-19 vaccination are needed.
